



Final Appraisal Recommendation
Advice No: 3815 – November 2015

Denosumab (Xgeva[®]▼) 120 mg solution for injection

Limited submission by Amgen Limited

Recommendation of AWMSG

Denosumab (Xgeva[®]) is recommended for use within NHS Wales for the treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity. This recommendation applies only in circumstances where the approved Patient Access Scheme is utilised.

Additional note(s):

- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1870), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

| | |
|---|---------------|
| Marketing authorisation holder on first issue | Amgen Limited |
| Date of first issue | November 2015 |
| Last reviewed | March 2019 |

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 3815:
denosumab (Xgeva[®]▼) 120 mg solution for injection. November 2015.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendations. Accreditation is valid for 5 years from October 2016. More information on accreditation can be viewed at <http://www.nice.org.uk/about/what-we-do/accreditation>